ReviewCureus2025
Metabolomic Biomarkers in Heart Failure: A Systematic Review of Diagnostic and Prognostic Significance.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Amino Acid-Derived Metabolic Signature Across Stages of Systolic Dysfunction: Derivation and Internal Evaluation of the HASI (Heart Failure Amino Acid-Derived Systolic Index)-40 Index.International journal of molecular sciences · 2026Article
- Dynamic navigation-based precision cardiac rehabilitation via blood metabolomics: from risk stratification to real-time intervention optimization.Frontiers in cardiovascular medicine · 2026Review
- Integrative multi-omics and network biology in cardiovascular disease: a systems-level framework for translational discovery.Frontiers in systems biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review evaluates the role of metabolomic biomarkers in the diagnosis, prognosis, and risk stratification of patients with heart failure (HF) across various phenotypes. A comprehensive literature search identified randomized controlled trials, cohort studies, and clinical trials that utilized validated metabolomic platforms, such as liquid chromatography-tandem mass spectrometry (LC-MS), gas chromatography-tandem mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) spectroscopy. Eligible studies assessed the relationship between metabolite profiles and key clinical outcomes, including NT-proBNP levels, six-minute walk distance (6MWD), hospitalization, and mortality. The included trials consistently identified significant associations between branched-chain amino acids (BCAAs), acylcarnitines, and phenylalanine with markers of HF severity and prognosis. Metabolomic profiling provided insight into altered energy metabolism, amino acid catabolism, and lipid oxidation pathways that underpin HF pathophysiology. Collectively, these findings highlight the potential of metabolomic biomarkers as valuable tools for early diagnosis, disease monitoring, and prognostic assessment in HF. Further large-scale, longitudinal studies are warranted to validate these biomarkers and facilitate their integration into precision cardiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.